Clinical trial NCT03506191: Pneumonia Due to Stenotrophomonas Maltophilia in ICUs
Official title: Pneumonia Due to Stenotrophomonas Maltophilia in Intensive Care Units: a Multicentre Retrospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pneumonia, Ventilator-Associated
Stenotrophomonas Infection
Critical Illness
Pneumonia, Bacterial
Keywords: Stenotrophomonas maltophilia
Pneumonia
Intensive Care Unit
Lead sponsor: Groupe Hospitalier Pitie-Salpetriere
Sponsor class: OTHER
First posted: 2018-04-24
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalized in Intensive Care Unit and presenting pneumonia due to Stenotrophomonas maltophilia

Brief summary: Pneumonia is a major cause of ICU admission, or may complicate ICU course. Among the causative pathogens, Stenotrophomonas Maltophilia is a rare pathogen, but affects usually patients with chronic pulmonary co-morbidities, or with long duration of mechanical ventilation and multiples treatment with broad spectrum antimicrobial therapy. However, there are only a paucity of data regarding epidemiology, impact and outcome of Pneumonia due to Stenotrophomonas Maltophilia in critically ill patients.

Primary objective was to study factors associated with mortality in case of Pneumonia due to Stenotrophomonas Maltophilia. Secondary objectives were to describe factors associated with morbidity of Pneumonia due to Stenotrophomonas Maltophilia (duration of mechanical ventilation, ICU length of stay), and to report the characteristics of critically ill patients presenting Pneumonia due to Stenotrophomonas Maltophilia.


Eligibility criteria: Inclusion Criteria:

Patients older than 18 years

Documented Stenotrophomonas maltophilia pneumonia:

* Clinical suspicion (≥ two criteria including: fever\> 38.5°C, leukocytosis \> 10\^9/L or leukopenia \< 4.10\^8/L, purulent tracheobronchial secretions and a new or persistent infiltrate on chest radiography).
* Documented Stenotrophomonas maltophilia positive quantitative culture of a respiratory sample: bronchoalveolar lavage fluid (significant threshold, \>10\^4cfu/ml) or plugged telescopic catheter (significant threshold, \>10\^3cfu/ml) or quantitative endotracheal aspirate (significant threshold, \>10\^6cfu/ml).

Exclusion Criteria:

* None

Primary outcomes:
measure: Treatment failure
timeFrame: Day 30
Secondary outcomes:
measure: Duration of mechanical ventilation
timeFrame: Day 30
measure: Recurrence of pneumonia due to Stenotrophomonas Maltophilia
timeFrame: Day 30
measure: Mortality
timeFrame: Day 30
Other outcomes:
Locations:
city: Paris
country: France
facility: Anesthesiology and Critical Care Medicine, Groupe Hospitalier Pitié-Salpêtrière
state: Ile-de-France
city: Metz
country: France
facility: Réanimation Polyvalente CHR Metz-Thionville
city: Nancy
country: France
facility: Department of Anesthesiology and Critical Care Medicine, University Hospital of NANCY
city: Strasbourg
country: France
facility: Department of Anesthesiology and Critical Care Medicine, University Hospital of Strasbourg
Study officials:
affiliation: APHP
name: Adrien Bouglé, MD
role: STUDY_DIRECTOR
affiliation: CHRU NANCY
name: Philippe Guerci, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Guerci P, Bellut H, Mokhtari M, Gaudefroy J, Mongardon N, Charpentier C, Louis G, Tashk P, Dubost C, Ledochowski S, Kimmoun A, Godet T, Pottecher J, Lalot JM, Novy E, Hajage D, Bougle A; AZUREA research network. Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care. 2019 Nov 21;23(1):371. doi: 10.1186/s13054-019-2649-5.